Search | VHL Regional Portal

Ultrafast 30-min infusion of a rituximab biosimilar (Truxima).

Pérez-Persona, Ernesto; Cuevas Palomares, Laida; Unamunzaga Cilaurren, Ariane; Gutiérrez López de Ocáriz, Xabier; Buendía Ureña, Buenaventura; Vega González de Viñaspre, Ana; Benito Ibarrondo, Begoña; Molinillo Fernández, María Carmen; Cordero Osúa, Ana; Benítez Delgado, Beatriz; García Albás, Juan José; Andrés Moralejo, Miguel Ángel; Guinea de Castro, José María.

EJHaem ; 4(4): 1196-1199, 2023 Nov.

Article in English | MEDLINE | ID: mdl-38024594

ABSTRACT

In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day-care hospital stays.

Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma.

Pérez-Persona, Ernesto; Oiartzabal-Ormategui, Itziar; Herraez, Susana; Menchaca, Carmen; Cuevas-Palomares, Laida; Santamaría-López, Ana; Díez-Angulo, Rosana; Robles-Castro, Diego; de Miguel-Sánchez, Carlos; Gabilondo-Jalón, Miren; Pisón-Herrero, Carlos; Unamunzaga-Cilaurren, Ariane; Vega González-Viñaspre, Ana; Salcedo-Cuesta, Laura; Mendizabal-Abad, Arantza; Guinea de Castro, José María.

Eur J Haematol ; 108(6): 532-535, 2022 06.

Article in English | MEDLINE | ID: mdl-35194853

Subject(s)

Melphalan , Multiple Myeloma , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bortezomib/adverse effects , Humans , Melphalan/therapeutic use , Multiple Myeloma/diagnosis , Multiple Myeloma/drug therapy , Prednisone/adverse effects , Treatment Outcome

Treatment burden in multiple myeloma according to comorbidity in real life.

Pérez Persona, Ernesto; Oiartzabal Ormategui, Itziar; Cuevas Palomares, Laida; Santamaría López, Ana; Robles de Castro, Diego; Miguel de Sánchez, Carlos; Gabilondo Jalón, Miren; Pisón Herrero, Carlos; Unamunzaga Cilaurren, Ariane; Vega González de Viñaspre, Ana; Guinea de Castro, Jose María.

Ann Hematol ; 101(2): 437-440, 2022 Feb.

Article in English | MEDLINE | ID: mdl-33674939

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Multiple Myeloma/drug therapy , Aged , Aged, 80 and over , Comorbidity , Disease Management , Female , Humans , Male , Middle Aged , Multiple Myeloma/epidemiology , Survival Analysis

ABSTRACT

Subject(s)

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL